Tracking neurodegenerative diseases in biofluids: Combining pathology and pathophysiology markers is the way

Andrea Mastrangelo¹, Angela Mammana², Piero Parchi³

Affiliations

¹ Department of Biomedical and Neuromotor Sciences (DiBiNeM), University of Bologna, Bologna, Italy.
² IRCCS, Istituto Delle Scienze Neurologiche di Bologna, Bologna, Italy.
³ Department of Biomedical and Neuromotor Sciences (DiBiNeM), University of Bologna, Bologna, Italy; IRCCS, Istituto Delle Scienze Neurologiche di Bologna, Bologna, Italy. Electronic address: piero.parchi@unibo.it.

PMID: 37977130
DOI: 10.1016/j.chembiol.2023.10.018

Free article

Comment

Tracking neurodegenerative diseases in biofluids: Combining pathology and pathophysiology markers is the way

Andrea Mastrangelo et al. Cell Chem Biol. 2023.

Free article

. 2023 Nov 16;30(11):1340-1342.

doi: 10.1016/j.chembiol.2023.10.018.

Authors

Andrea Mastrangelo¹, Angela Mammana², Piero Parchi³

Affiliations

¹ Department of Biomedical and Neuromotor Sciences (DiBiNeM), University of Bologna, Bologna, Italy.
² IRCCS, Istituto Delle Scienze Neurologiche di Bologna, Bologna, Italy.
³ Department of Biomedical and Neuromotor Sciences (DiBiNeM), University of Bologna, Bologna, Italy; IRCCS, Istituto Delle Scienze Neurologiche di Bologna, Bologna, Italy. Electronic address: piero.parchi@unibo.it.

PMID: 37977130
DOI: 10.1016/j.chembiol.2023.10.018

Abstract

Biofluid biomarkers to track neurodegenerative diseases in vitam are urgently needed. Recent studies show that large-scale proteomic analyses based on the proximity extension assay may reveal novel biomarkers reflecting disease pathophysiology. Such biomarkers will likely express their maximal clinical value when used in combination with pathology-specific biomarkers.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests The authors declare no competing interests.

Comment on

Large-scale proximity extension assay reveals CSF midkine and DOPA decarboxylase as supportive diagnostic biomarkers for Parkinson's disease.
Paslawski W, Khosousi S, Hertz E, Markaki I, Boxer A, Svenningsson P. Paslawski W, et al. Transl Neurodegener. 2023 Sep 4;12(1):42. doi: 10.1186/s40035-023-00374-w. Transl Neurodegener. 2023. PMID: 37667404 Free PMC article.
CSF proteome profiling reveals biomarkers to discriminate dementia with Lewy bodies from Alzheimer´s disease.
Del Campo M, Vermunt L, Peeters CFW, Sieben A, Hok-A-Hin YS, Lleó A, Alcolea D, van Nee M, Engelborghs S, van Alphen JL, Arezoumandan S, Chen-Plotkin A, Irwin DJ, van der Flier WM, Lemstra AW, Teunissen CE. Del Campo M, et al. Nat Commun. 2023 Sep 13;14(1):5635. doi: 10.1038/s41467-023-41122-y. Nat Commun. 2023. PMID: 37704597 Free PMC article.
DOPA decarboxylase is an emerging biomarker for Parkinsonian disorders including preclinical Lewy body disease.
Pereira JB, Kumar A, Hall S, Palmqvist S, Stomrud E, Bali D, Parchi P, Mattsson-Carlgren N, Janelidze S, Hansson O. Pereira JB, et al. Nat Aging. 2023 Oct;3(10):1201-1209. doi: 10.1038/s43587-023-00478-y. Epub 2023 Sep 18. Nat Aging. 2023. PMID: 37723208 Free PMC article.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Tracking neurodegenerative diseases in biofluids: Combining pathology and pathophysiology markers is the way

Affiliations

Tracking neurodegenerative diseases in biofluids: Combining pathology and pathophysiology markers is the way

Authors

Affiliations

Abstract

Conflict of interest statement

Comment on

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical